Converting from Carbamazepine (Tegretol) to Levetiracetam (Keppra)
Start levetiracetam at 500 mg twice daily while maintaining the current carbamazepine dose, then gradually taper carbamazepine by 200 mg every 1-2 weeks while monitoring closely for both seizure breakthrough and signs of carbamazepine toxicity.
Conversion Protocol
Initial Phase: Cross-Titration Strategy
- Begin levetiracetam at 500 mg twice daily (1000 mg/day total) while keeping carbamazepine at its current dose 1, 2
- Maintain both medications for at least 1-2 weeks to establish therapeutic levetiracetam levels and ensure seizure control
- Monitor closely during this overlap period, as a pharmacodynamic interaction exists where levetiracetam can precipitate carbamazepine toxicity even without changes in carbamazepine blood levels 3, 4
Carbamazepine Taper
The FDA label for Tegretol emphasizes gradual changes when adding or removing anticonvulsants 1. Based on this guidance:
- Reduce carbamazepine by 200 mg every 1-2 weeks (or proportionally for pediatric patients)
- Slower tapering is safer - consider 2-week intervals if the patient has been on carbamazepine long-term or has frequent seizures
- Never abruptly discontinue carbamazepine due to seizure risk
Levetiracetam Dose Optimization
- Most patients respond to initial dosing: 80-86% of patients achieving seizure control do so at the starting dose of 500 mg twice daily 5
- If seizures occur during conversion: Increase levetiracetam by 500 mg/day increments weekly up to 1500 mg twice daily (3000 mg/day maximum) 2
- Target therapeutic range: 12-46 μg/mL, though routine monitoring is not required 6
Critical Safety Considerations
Pharmacodynamic Interaction Warning
This is the most important pitfall to avoid: Levetiracetam causes carbamazepine toxicity through a pharmacodynamic (not pharmacokinetic) mechanism 3, 7, 4. This means:
- Carbamazepine blood levels remain unchanged but toxicity symptoms appear
- The odds of carbamazepine toxicity increase 16-fold when levetiracetam is added 4
- Risk is highest when the LEV:CBZ dose ratio exceeds 1.86 4
Watch for carbamazepine toxicity symptoms:
- Dizziness, ataxia, diplopia
- Sedation, confusion
- Nausea
If toxicity occurs: Either reduce carbamazepine dose more aggressively or temporarily reduce levetiracetam dose during the overlap period.
Monitoring During Conversion
- Clinical assessment weekly during active conversion
- Seizure diary to track breakthrough seizures
- Carbamazepine levels are optional but may be reassuring - remember that normal levels don't exclude toxicity during levetiracetam co-administration 3
- Renal function should be checked, as levetiracetam is renally cleared and requires dose adjustment if creatinine clearance is reduced 7
Population-Specific Considerations
Elderly Patients
- Levetiracetam has a longer half-life (10-11 hours vs 6-8 hours in younger adults) 7
- Advantage: Levetiracetam causes significantly fewer cognitive impairments than carbamazepine in elderly patients 8
- Consider slower carbamazepine taper (2-week intervals)
Pediatric Patients
- Children eliminate levetiracetam faster (half-life 5-7 hours) 7
- Start at age-appropriate doses per FDA labeling 2
- Evidence supports equivalence: Both drugs achieve similar seizure freedom rates in children, but levetiracetam has fewer dermatologic adverse events 9
Renal Impairment
- Dose adjustment required for levetiracetam if CrCl < 80 mL/min 7
- This is a major advantage of switching from carbamazepine, which is hepatically metabolized
Expected Outcomes
Based on comparative effectiveness data 5, 8:
- Seizure freedom rates are equivalent between the two drugs (approximately 73%)
- Tolerability favors levetiracetam: Lower withdrawal rates due to adverse events (14.4% vs 19.2%) 5
- Cognitive function is better preserved with levetiracetam, particularly attention and executive function 8
Timeline Summary
| Week | Action |
|---|---|
| 0 | Start LEV 500 mg BID, continue full CBZ dose |
| 1-2 | Monitor for CBZ toxicity and seizures |
| 2-4 | Reduce CBZ by 200 mg, continue LEV 500 mg BID |
| 4-6 | Reduce CBZ by another 200 mg |
| Continue | Taper CBZ by 200 mg every 1-2 weeks until discontinued |
| As needed | Increase LEV if seizures occur (max 1500 mg BID) |
The entire conversion typically takes 4-12 weeks depending on the starting carbamazepine dose and patient tolerance.